Se Hoon Park

机构：Samsung Medical Center, Sungkyunkwan University

发表论文 662 篇 · 总被引 31135 次 · h-index 73

代表论文

• ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer (2025 · New England Journal of Medicine · 被引 117)
• Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial (2025 · Annals of Oncology · 被引 62)
• Adjuvant nivolumab versus placebo for high-risk muscle-invasive urothelial carcinoma: 5-year efficacy and ctDNA results from CheckMate 274 (2025 · Annals of Oncology · 被引 33)
• Pembrolizumab plus Lenvatinib in patients with metastatic Renal Cell Carcinoma: real-world evidences from the international ARON- 1 study (2025 · Cancer Immunology Immunotherapy · 被引 10)
• Avelumab First-line Maintenance for Advanced Urothelial Carcinoma: Long-term Outcomes from the JAVELIN Bladder 100 Trial in Patients with Nonvisceral or Lymph Node–only Disease (2025 · European Urology · 被引 7)
• Exploratory analysis of responders from the phase 3 EV-302 trial of enfortumab vedotin plus pembrolizumab (EV+P) vs chemotherapy (chemo) in previously untreated locally advanced or metastatic urothelial carcinoma (la/mUC). (2025 · Journal of Clinical Oncology · 被引 7)